4.7 Article

Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae

期刊

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 59, 期 12, 页码 7830-7832

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01583-15

关键词

-

资金

  1. Merck, Inc.
  2. Astellas, Inc.
  3. Pfizer
  4. Mylan, Inc.
  5. T2 Biosystems
  6. Astellas
  7. Cubist
  8. Theravance
  9. Medicines Company
  10. Novartis
  11. Merck
  12. ContraFect
  13. Drais
  14. iCo
  15. MethylGene
  16. Sigma Tau
  17. Trius

向作者/读者索取更多资源

Triazole prophylaxis has become the norm in patients with hematological malignancies. Breakthrough infections caused by Mucorales during triazole prophylaxis remain a challenging problem. We found that preexposure of Rhizopus oryzae to antifungal triazoles (fluconazole, voriconazole, posaconazole, and itraconazole) did not modify the in vitro susceptibility of Rhizopus oryzae to posaconazole. In contrast, preexposure of Rhizopus to triazoles was associated with the enhanced in vitro susceptibility of R. oryzae to amphotericin B. Preexposure to posaconazole did not alter the virulence of R. oryzae in the fly model of mucormycosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据